CABA - CIK 0001759138
Cabaletta Bio, Inc. trades as CABA. This page tracks Cabaletta Bio, Inc. through 423 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| Major company event | 8-K | 2026-05-04 |
| Prospectus supplement | 424B5 | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| Annual report to shareholders | ARS | 2026-04-28 |
The largest companies sharing Cabaletta Bio, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
In its latest fiscal year Cabaletta Bio, Inc. reported a net loss of $167.86M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.